Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex's CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). Vertex generated more than $10 billion in sales from its CF drugs in 2023. The trend is expected to continue in 2024. While CF remains the main area of focus, Vertex has seen rapid success in its non-CF pipeline candidates' development in the past year. Vertex and partner CRISPR Therapeutics ' CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in multiple regions in late 2023/early 2024. Casgevy' approval has diversified its commercial opportunity. So far this year, the stock has risen 16.5% against the industry's 4.6% decline. The stock has also outperformed the sector as well as the S&P 500. VRTX Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Casgevy Diversifies C
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued." [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $88.00 price target on the stock.MarketBeat
- CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 6/24/24 - Form 4
- 6/3/24 - Form 8-K
- 5/31/24 - Form 4
- CRSP's page on the SEC website